Clinical trials: Urinary Complications
Vulvar Atrophy, Vulvovaginal Signs and Symptoms
Retrospective Cohort Study of Symptoms and Quality of Life in Women With Genitourinary Syndrome of Menopause.
The goal of this clinical trial is to retrospectively identify the most prevalent symptoms of genitourinary syndrome of menopause (GSM) among postmenopausal women and to evaluate their impact on quality of life.
- Conditions
- Vulvar Atrophy, Vulvovaginal Signs and Symptoms, Genitourinary Syndrome of Menopause (GSM), Quality of Life
- Trial name
- NCT07737782
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Mucosa Innovations, S.L.
Non-muscle-invasive Bladder Cancer, NMIBC
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
- Conditions
- Non-muscle-invasive Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms
- Trial name
- NCT05483868
- Testing
- AU-011, AU-011 in Combination with Medical Laser Adminstration, AU-011 in Combination with Medical Laser Administration
- Where
- 19 sites in United States, Australia
- Volunteers
- 55 people
- Sponsor
- Aura Biosciences
Urgency Incontinence, Urinary Bladder Overactive
A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
A study to understand the impact of Betmiga® on patients quality of life, satisfaction with treatment, how long patients remain on treatment, patterns of healthcare resource utilisation, and safety as prescribed by the physicians…
- Conditions
- Urgency Incontinence, Urinary Bladder Overactive, Overactive Bladder, Urologic Diseases
- Trial name
- BELIEVE (NCT02320773)
- Testing
- Betmiga®
- Where
- 60 sites in Czechia, Denmark and 6 more
- Volunteers
- 863 people
- Sponsor
- Astellas Pharma Europe Ltd.
Stress Urinary Incontinence, Cell Therapy
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
This is a clinical investigation approved by US FDA and Canadian Health Authority to study the safety and potential effectiveness of the autologous muscle cells for the treatment of stress urinary incontinence.
- Trial name
- NCT00847535
- Testing
- autologous muscle cell injection
- Where
- 3 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Cook MyoSite
Urinary Bladder, Overactive
A Study of YM178 in Patients With Symptomatic Overactive Bladder
Examine which dose of YM178 is the best in terms of efficacy, safety and tolerability compared to placebo
- Trial name
- NCT00527033
- Testing
- YM178
- Where
- 5 sites in Japan
- Volunteers
- 842 people
- Sponsor
- Astellas Pharma Inc
Urinary Tract Infections
Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
Researchers want to find out if a drug called Cipro® XR (ciprofloxacin extended-release) can help people with a complicated urinary tract infection caused by a kind of bacteria called Pseudomonas aeruginosa.
- Trial name
- NCT00481689
- Testing
- Cipro XR (Ciprofloxacin, BAYQ3939)
- Where
- 35 sites in United States
- Volunteers
- 500 people
- Sponsor
- Bayer
Urinary Incontinence, Fecal Incontinence
Incontinence Management System ICU Field Evaluation
The objective of this Field Evaluation is to assess usage and satisfaction associated with the Hill-Rom Incontinence Management System.
- Trial name
- NCT03628833
- Testing
- Incontinence Management System
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hill-Rom
Urinary Incontinence
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication therapy.
- Trial name
- NCT00230789
- Testing
- Tolterodine ER 4 mg QD, OAB Patient Behavioral Training Material
- Where
- 51 sites in United States
- Volunteers
- 417 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Cough
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)
The purpose of this study is to evaluate the efficacy and safety of gefapixant, in improving symptoms of cough-induced stress urinary incontinence (SUI) in adult female participants with refractory or unexplained chronic cough.
- Trial name
- NCT04193176
- Testing
- Gefapixant
- Where
- 90 sites in United States, Argentina and 10 more
- Volunteers
- 376 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystinuria
Bucillamine Phase 2 Trial in Patients With Cystinuria
Subjects on a standard regimen of tiopronin (cystine binding thiol drug; CBTD) plus prescribed first-line therapy (i.e. on a hydration, alkali therapy and dietary restriction) who are failing therapy will be selected for this…
- Trial name
- NCT02942420
- Testing
- Bucillamine
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Revive Therapeutics, Ltd.
Overactive Bladder, Urge Incontinence
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI).
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03556891
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 15 sites in United States
- Volunteers
- 133 people
- Sponsor
- Valencia Technologies Corporation
Bladder Neoplasm
Virtuoso Improving Anatomic Bladder Lesion Excision (VIABLE) Trial
A robotic assisted surgery for bladder lesion excision.
- Trial name
- NCT06940648
- Testing
- The study is to evaluate the use of the Virtuoso Endoscopy System to perform safe and effective bladder lesion excisions.
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Virtuoso Surgical, Inc.
Prostate Cancer, Melanoma
Safety Study of MGA271 in Refractory Cancer
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer.
- Conditions
- Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT01391143
- Testing
- MGA271
- Where
- 12 sites in United States
- Volunteers
- 179 people
- Sponsor
- MacroGenics
E.Coli Infections
Vaccine Against Escherichia Coli Infection
This Phase I multi-center placebo controlled study is conducted in healthy women with a history of recurrent urinary tract infections (UTI) aged between 18 and 70 years.
- Trial name
- NCT02289794
- Testing
- E.coli bioconjugate vaccine
- Where
- Switzerland
- Volunteers
- 194 people, healthy volunteers welcome
- Sponsor
- GlycoVaxyn AG
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Overactive Bladder
Clinical Feasibility Study, Implantable Tibial Nerve Stimulator (ITNS)
Study objectives: To report feasibility data for safety and effectiveness of the study device. Study device: Nine Continents Medical implantable tibial nerve stimulator (ITNS) model 9C-680 with programmer model 9C-580.
- Trial name
- NCT04115228
- Testing
- Implantation and neuromodulation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Nine Continents Medical, Inc.
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.
Urinary Stress Incontinence
Biomechanical Effects of Duloxetine on Bladder and Sphincter Muscle Function in Women in Pure Genuine Stress Incontinence
Double-blind placebo-controlled study of the biomechanical effects of duloxetine compared with placebo in the treatment of women with pure genuine stress incontinence
- Trial name
- NCT00190567
- Testing
- duloxetine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Eli Lilly and Company
Urinary Bladder, Overactive
FemPulse Therapy First-in-Human Experience
The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.
- Trial name
- NCT03874637
- Testing
- Treament
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- FemPulse Corporation
Overactive Bladder
An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).
This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in participants with OAB for up to 52 weeks.
- Trial name
- Empowur (NCT03583372)
- Testing
- Vibegron, Tolterodine Tartrate ER
- Where
- 107 sites in United States
- Volunteers
- 506 people
- Sponsor
- Urovant Sciences GmbH
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.